Dignitana AB, leader in scalp cooling innovation, has installed the new DigniCap Delta® scalp cooling device at the UCLA Cancer Center Santa Monica Parkside and will begin providing scalp cooling at Cedars-Sinai Tower Hematology Oncology Medical Group in late September. DigniCap is indicated to prevent chemotherapy-induced hair loss in patients with solid tumors. The newest DigniCap device received clearance from the United States Food and Drug Administration in June 2019 and is the fourth generation of The DigniCap® Scalp Cooling System.
“The technological advances engineered into the new DigniCap Delta bring scalp cooling therapy to a whole new level,” said William Cronin, Chief Executive Officer of Dignitana AB. “This streamlined model offers a new gold standard in patient comfort, flexibility and precision fit and is designed for ease of use and efficiency by clinicians. We are proud that UCLA-Santa Monica and Cedars-Sinai Tower have chosen to offer their patients scalp cooling with DigniCap Delta.”
The new DigniCap Delta system includes solid state cooling for precise temperature control and a streamlined design that is 54 percent smaller than the previous model. A new cap system gives patients a flexible Cooling Wrap and an adjustable Thermal Cap designed to optimize scalp cooling outcomes and minimize clinic storage needs. The intuitive user interface provides up to an 80 percent reduction in nursing time per patient infusion compared to the current model.
DigniCap Delta is now available to medical centers throughout the United States with the current scalp cooling system already available in in 30 U.S. states and 37 countries around the globe. UCLA’s Jonsson Comprehensive Cancer Center participated in early clinical trials that paved the way for FDA clearance of the original DigniCap Scalp Cooling System.